Loading company…
Suzhou Dima Biotechnology develops recombinant monoclonal antibodies for tumor immunotherapy, based in Suzhou, China.
Based in Suzhou, China and established in 2019, Suzhou Dima Biotechnology researches and develops recombinant monoclonal antibodies for tumor immunotherapy, using its self-developed RECmAb digital monoclonal antibody technology. In September 2019 it closed angel funding from Guoqian Venture Capital and Huatai Zijin Investment, with another unspecified investor also participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in